Literature DB >> 8411553

Clinical effectiveness of influenza vaccination in Manitoba.

D S Fedson1, A Wajda, J P Nicol, G W Hammond, D L Kaiser, L L Roos.   

Abstract

OBJECTIVE: To assess the clinical effectiveness of influenza vaccination in preventing influenza-associated hospitalization and death.
DESIGN: Case-control study. SETTING AND PATIENTS: Noninstitutionalized persons aged 45 years or older living in Manitoba, on December 1, 1982, and December 1, 1985.
METHODS: Linked records of the Manitoba population registry, hospital-discharge abstracts, physician claims for ambulatory-patient visits and influenza vaccination, and vital statistics were used. A matched-set analysis estimated the clinical effectiveness of influenza vaccination in preventing hospital admissions and deaths from influenza-associated conditions during influenza A (H3N2) outbreak periods in 1982 to 1983 (12 weeks) and 1985 to 1986 (10 weeks). The analysis adjusted for hospital discharge and ambulatory care for high-risk conditions within the previous 15 months and 3 months, respectively.
RESULTS: Influenza vaccination prevented 32% to 39% of hospital admissions with pneumonia and influenza and 15% to 34% of admissions with all respiratory conditions. Vaccination was 43% to 65% effective in preventing hospital deaths with these conditions (all listed diagnoses) and 27% to 30% effective in preventing deaths from all causes.
CONCLUSION: Influenza vaccination has substantial clinical effectiveness in preventing hospital admission and death from influenza-associated conditions in noninstitutionalized individuals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411553

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  57 in total

1.  Measuring the impact of influenza on the hospital admission rates of the elderly in Ontario: a five-year admission rate analysis, 1988-1993.

Authors:  R E Upshur; V Goel
Journal:  Can J Public Health       Date:  2000 Mar-Apr

Review 2.  Individual and community impact of influenza.

Authors:  A S Monto
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 3.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

4.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

5.  The privacy paradox: laying Orwell's ghost to rest.

Authors:  R E Upshur; B Morin; V Goel
Journal:  CMAJ       Date:  2001-08-07       Impact factor: 8.262

6.  Effectiveness of influenza vaccination in the elderly in a community in Italy.

Authors:  E Crocetti; S Arniani; F Bordoni; G Maciocco; M Zappa; E Buiatti
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 7.  Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications.

Authors:  E Hak; Th J M Verheij; D E Grobbee; K L Nichol; A W Hoes
Journal:  J Epidemiol Community Health       Date:  2002-12       Impact factor: 3.710

Review 8.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

9.  Economic evaluation of vaccination against influenza in New Zealand.

Authors:  W G Scott; H M Scott
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 10.  Evaluating the impact of influenza vaccination. A North American perspective.

Authors:  D S Fedson
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.